CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator

CD44(+)/CD24(-) or aldehyde dehydrogenase 1 (ALDH1) has been suggested as a potential marker for breast cancer stem cells. In the cohort of 819 patients with resected ER-positive breast cancer, the ‘5-year relapse group’ within 5 years postsurgery during adjuvant tamoxifen treatment and the ‘non-rel...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Moon, Yong Wha, An, Hee-Jung, Koo, Ja Seung, Kim, Gun Min, Han, Hyunju, Park, Seho, Kim, Seung Il, Park, Hyung Seok, Kim, Sewha, Kim, Seung Ki, Lee, Seung Ah, Hwang, Sohyun, Son, Gun Woo, Sohn, Joohyuk
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5788664/
https://ncbi.nlm.nih.gov/pubmed/29416796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23519
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items